logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


Buyout Speculation Boosts This Biotechnology Stock

By  +Follow June 11, 2014 8:05AM
Share:
Tickers Mentioned:

While equity markets edged lower Tuesday, one small cap stock in the biotechnology sector surged, extending its gains from previous trading sessions. Shares of Achillion Pharmaceuticals Inc. (ACHN) , a biopharmaceutical company focused on the development and commercialization of treatment for infectious diseases, have surged in early trading on Tuesday on ongoing buyout speculation.

Stock Continues to Gain Momentum

After surging more than 47% in Monday’s trading session, shares of Achillion Pharmaceuticals gained another 83% on Tuesday to close at $7.79. The trading volume of 27.15 million is more than 10 times the daily average volume of 2.66 million. With the entire trading day still left, Achillion shares could see a significant spike in volume.

Achillion Pharmaceuticals shares have now gained more than 170% in the last three trading sessions. Despite the surge, the stock is still trading below its 52-week high of $8.49. However, the surge has pushed the small cap stock above its 50-day and 200-day moving averages. The stock’s MACD has also crossed the signal line and the zero-line, which is a strong bullish signal.

Buyout Rumors Spark Rally

The rally in Achillion Pharmaceuticals shares has been sparked by rumors of a takeover. The takeover speculation began after Merck (MRK) announced the acquisition of the company’s rival Idenix Pharmaceuticals Inc. (IDIX) .

Achillion Pharmaceuticals shares have got a further boost following news that the U.S. FDA has allowed the company to conduct trials in patients with hepatitis C.

Milind Deshpande, Ph.D., President and CEO of Achillion Pharmaceuticals, noted that the company remains focused on developing regimens using ACH-3422 and ACH-3102, its second-generation Phase 2 NS5A inhibitor. Deshpande added that the second half of 2014 will feature multiple milestones in that program. 

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

				
				
By  +Follow June 11, 2014 8:05AM
Share:

Comments

 

blog comments powered by Disqus

 Today's Must Reads

Beyond Twitter: 5 Small-Cap Tech Plays Nobody’s Talking About


Will the Fed Continue Its Track Record of Unprecedented Moves?

Facebook versus Google: Who Rules the Internet?

Are These the Worst Business Documentaries on Netflix?


Saving the

Small-Cap Market

 

Small-cap stocks offer investors many benefits, ranging from higher growth potential to overlooked value opportuni... in Equities.com's Hangs on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN